Sage Therapeutics (Sage Therapeutics) GF Score : 44/100 (As of May. 16, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics GF Score?

Sage Therapeutics has the GF Score of 44, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 1/10
3. Growth Rank : 1/10
4. GF Value Rank : 2/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Sage Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Sage Therapeutics's GF Score

For the Biotechnology subindustry, Sage Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sage Therapeutics's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sage Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Sage Therapeutics's GF Score falls into.

Sage Therapeutics (NAS:SAGE) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Sage Therapeutics GF Score Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics (Sage Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (NAS:SAGE) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

SG7:Germany SG7:Germany

Address

215 First Street, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Executives

Elizabeth Barrett	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jessica Federer	director	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Jeffrey M Jonas	director, officer: See Remarks	ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Barry E Greene	director	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Laura Gault	officer: Chief Medical Officer	C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Benecchi	officer: Chief Commercial Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
James M Frates	director	88 SIDNEY ST, CAMBRIDGE MA 021394136
Biogen Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Biogen Ma Inc.	10 percent owner	225 BINNEY STREET, CAMBRIDGE MA 02142
Albert Robichaud	officer: Chief Scientific Officer	215 FIRST STREET, CAMBRIDGE MA 02142
Michael Cloonan	officer: Chief Business Officer	C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142
Anne Marie Cook	officer: General Counsel	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Steven M Paul	director	C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Kimi Iguchi	officer: See Remarks	100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035